Luxturna
Sales and Marketing/ Views & Analysis/ Views and analysis
Finding the right reimbursement model for gene therapies
George Underwood
CAR T, cell therapy, gene therapy, kantar, Kyrmriah, Luxturna, pricing
0 Comment
Roche insists Spark deal is still on, despite lacklustre take-up
Phil Taylor
gene therapy, Luxturna, Roche, Spark Therapeutics
0 Comment
R&D/ Views & Analysis/ Views and analysis
Will cell and gene therapies disrupt reimbursement?
Dominic Tyer
cell and gene therapy, cell therapy, Deep Dive: Disruptive Technologies, gene therapy, Kymriah, Luxturna, PhRMA, Yescarta
0 Comment
Cancer/ News/ R&D/ Top stories
Novartis snaps up ex-US partnership with Spark on gene therapy
Andrew McConaghie
cell and gene therapy, Luxturna, Novartis, Spark Therapeutics
0 Comment
Healthcare/ Market Access/ News/ News/ Pharma Market Access/ R&D
Can Spark make a profit on its groundbreaking gene therapy?
Andrew McConaghie
cell and gene therapy, gene therapy, Luxturna, Rare diseases, Spark Therpeutics
0 Comment